Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies

• Published in: CPT: pharmacometrics and systems pharmacology Vol. 12; no. 7; pp. 904 - 915
• Main Authors: Tardivon, Coralie, Loingeville, Florence, Donnelly, Mark, Feng, Kairui, Sun, Wanjie, Sun, Guoying, Grosser, Stella, Zhao, Liang, Fang, Lanyan, Mentré, France, Bertrand, Julie
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2023; American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics; John Wiley and Sons Inc; Wiley
• Subjects: Area Under Curve; Bioequivalence; Cross-Over Studies; Decomposition; Estimates; Generic drugs; Humans; Hypotheses; Methodology; Pharmacokinetics; Statistics; Therapeutic Equivalency; United States > US
• ISSN: 2163-8306; 2163-8306
• DOI: 10.1002/psp4.12960

In a traditional pharmacokinetic (PK) bioequivalence (BE) study, a two‐way crossover study is conducted, PK parameters (namely the area under the time‐concentration curve [AUC] and the maximal concentration [Cmax]) are obtained by noncompartmental analysis (NCA), and the BE analysis is performed using the two one‐sided test (TOST) method. For ophthalmic drugs, however, only one sample of aqueous humor, in one eye, per eye can be obtained in each patient, which precludes the traditional BE analysis. To circumvent this issue, the U.S. Food and Drug Administration (FDA) has proposed an approach coupling NCA with either parametric or nonparametric bootstrap (NCA bootstrap). The model‐based TOST (MB‐TOST) has previously been proposed and evaluated successfully for various settings of sparse PK BE studies. In this paper, we evaluate, via simulations, MB‐TOST in the specific setting of single sample PK BE study and compare its performance to NCA bootstrap. We performed BE study simulations using a published PK model and parameter values and evaluated multiple scenarios, including study design (parallel or crossover), sampling times (5 or 10 spread across the dosing interval), and geometric mean ratio (of 0.8, 0.9, 1, and 1.25). Using the simulated structural PK model, MB‐TOST performed similarly to NCA bootstrap for AUC. For Cmax, the latter tended to be conservative and less powerful. Our research suggests that MB‐TOST may be considered as an alternative BE approach for single sample PK studies, provided that the PK model is correctly specified and the test drug has the same structural model as the reference drug.